NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis $0.95 +0.04 (+4.93%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$0.96 +0.00 (+0.43%) As of 10/3/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Marker Therapeutics Stock (NASDAQ:MRKR) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Marker Therapeutics alerts:Sign Up Key Stats Today's Range$0.90▼$0.9950-Day Range$0.85▼$1.5552-Week Range$0.81▼$5.95Volume489,529 shsAverage Volume278,535 shsMarket Capitalization$12.36 millionP/E RatioN/ADividend YieldN/APrice Target$13.17Consensus RatingBuy Company Overview Marker Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies. Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers. The company has initiated early-phase clinical studies in patients with HPV16-positive head and neck cancers, as well as exploratory trials in other solid tumor indications. Marker conducts its research and development activities at its headquarters in Houston, Texas, and collaborates with academic and clinical partners across the United States to support trial enrollment and translational research efforts. Founded in 2019 through a corporate reorganization and public listing, Marker Therapeutics transitioned its focus from earlier-stage RNA-based programs to cell-based immunotherapies. The company is guided by a management team experienced in cell therapy development, process scale-up and regulatory strategy. With an emphasis on personalized medicine, Marker is advancing its pipeline toward later-stage studies and exploring combination approaches alongside established oncology agents.AI Generated. May Contain Errors. Read More Marker Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks81st Percentile Overall ScoreMRKR MarketRank™: Marker Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 197th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingBuy Consensus RatingMarker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialMarker Therapeutics has a consensus price target of $13.17, representing about 1,278.9% upside from its current price of $0.95.Amount of Analyst CoverageMarker Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Marker Therapeutics are expected to decrease in the coming year, from ($0.65) to ($2.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Marker Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Marker Therapeutics is -0.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Marker Therapeutics' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted9.40% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 30.84%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Sustainability and ESG3.9 / 5Environmental Score-0.75 Percentage of Shares Shorted9.40% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 0.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 30.84%, indicating that investor sentiment is improving significantly. News and Social Media2.8 / 5News SentimentN/A News SentimentMarker Therapeutics has a news sentiment score of 1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Marker Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 3 people have searched for MRKR on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat Follows4 people have added Marker Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.80% of the stock of Marker Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MRKR Stock News HeadlinesMarker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment ConferenceAugust 28, 2025 | globenewswire.comMarker Therapeutics (MRKR) Falls 20.6% After Positive Clinical StudyAugust 27, 2025 | insidermonkey.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 5 at 2:00 AM | StockEarnings (Ad)Marker Therapeutics stock soars on promising Phase 1 lymphoma study dataAugust 26, 2025 | investing.comMarker Therapeutics provides update on observations from Phase 1 APOLLO studyAugust 26, 2025 | msn.comMarker Therapeutics Stock Drops After Report About Lymphoma TreatmentAugust 26, 2025 | benzinga.comMarker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed LymphomaAugust 26, 2025 | globenewswire.comMarker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth ConferenceJuly 30, 2025 | globenewswire.comSee More Headlines MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed this year? Marker Therapeutics' stock was trading at $3.11 on January 1st, 2025. Since then, MRKR stock has decreased by 69.3% and is now trading at $0.9549. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.55) by $0.26. The company earned $0.86 million during the quarter, compared to analyst estimates of $0.72 million. Marker Therapeutics had a negative trailing twelve-month return on equity of 114.59% and a negative net margin of 271.12%. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include SCYNEXIS (SCYX), Tesla (TSLA), Meta Platforms (META), Pfizer (PFE), NVIDIA (NVDA), Viking Therapeutics (VKTX) and OPKO Health (OPK). Company Calendar Last Earnings8/14/2025Today10/05/2025Next Earnings (Estimated)11/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:MRKR CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees60Year Founded2018Price Target and Rating Average Price Target for Marker Therapeutics$13.17 High Price Target$19.00 Low Price Target$8.00 Potential Upside/Downside+1,278.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($1.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$10.73 million Net Margins-271.12% Pretax Margin-270.17% Return on Equity-114.59% Return on Assets-90.31% Debt Debt-to-Equity RatioN/A Current Ratio3.45 Quick Ratio3.45 Sales & Book Value Annual Sales$6.59 million Price / Sales1.88 Cash FlowN/A Price / Cash FlowN/A Book Value$1.73 per share Price / Book0.55Miscellaneous Outstanding Shares12,940,000Free Float11,930,000Market Cap$12.36 million OptionableNot Optionable Beta1.47 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (NASDAQ:MRKR) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.